—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Certara Inc (CERT) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for CERT, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.90 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How CERT has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.90 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Certara Inc moved 0.90% on average · correlation 0.14 · higher than 83% of US names
  • Beta, last 3 months 0.59 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.07% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +2.89% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Health Information Services · 8 names with week and year-to-date

Peer group

Health Information Services

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against CERT on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Certara Inc

CERT in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Certara builds software and services used to simulate how drugs behave in the body before and during clinical trials, a field it calls biosimulation. Its Simcyp platform models pharmacokinetics, the way a drug moves through the body, while Phoenix and Pirana support the statistical modelling regulators expect in a submission. It also sells Chemaxon chemistry software for compound design and Pinnacle 21 tools that check clinical trial data against required formats. Certara is based in Radnor, Pennsylvania, and serves drug developers, biotech firms and regulators worldwide.
Where it sits in the stack
Certara has no seat in Rubin or Halo, our indices for the AI hardware and software build-out; it sits instead in the healthcare sleeve of our universe, within health information services. Its software supports drug discovery and regulatory review rather than chip or data-centre production, so it is a customer of computing infrastructure rather than a constituent of it.
Who it is priced against
Closelooknet has not assigned a peer group to Certara. The market sometimes compares it with Simulations Plus, another maker of drug-simulation software used in similar stages of development.
Why Closelooknet tracks it
Certara sits in the Russell 1000 but carries no Rubin or Halo seat and does not yet carry a Closelooknet score; the diary has not quoted it in the Morning 10 or other editions to date.
What the diary watches
Closelooknet watches whether Certara's shares stabilise after slipping below their 200-day average, since continued weakness would suggest the market expects softer demand for biosimulation ahead of coming drug submissions.

Certara Inc (CERT) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Certara Inc (CERT)?

Certara Inc trades as CERT on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is CERT in a Closelooknet index?

Not currently — Certara Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does CERT trade against its moving averages?

Bullish stack, 200-day still turning: Trades +13.4% vs the 50-day and +27% vs the 200-day average, 34.4% below the 52-week high and +104.7% off the 52-week low; a golden cross printed 22 sessions ago. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Certara Inc trade when bond yields rise?

Over the past year Certara Inc had a beta of 0.90 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 83% of US names. On the 10 sessions in which long bonds fell most it moved −1.07% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Certara Inc do?

Certara builds software and services used to simulate how drugs behave in the body before and during clinical trials, a field it calls biosimulation. Its Simcyp platform models pharmacokinetics, the way a drug moves through the body, while Phoenix and Pirana support the statistical modelling regulators expect in a submission. It also sells Chemaxon chemistry software for compound design and Pinnacle 21 tools that check clinical trial data against required formats. Closelooknet has not assigned a peer group to Certara. The market sometimes compares it with Simulations Plus, another maker of drug-simulation software used in similar stages of development.

Where does Certara Inc sit in the AI build-out?

Certara has no seat in Rubin or Halo, our indices for the AI hardware and software build-out; it sits instead in the healthcare sleeve of our universe, within health information services. Its software supports drug discovery and regulatory review rather than chip or data-centre production, so it is a customer of computing infrastructure rather than a constituent of it. Certara sits in the Russell 1000 but carries no Rubin or Halo seat and does not yet carry a Closelooknet score; the diary has not quoted it in the Morning 10 or other editions to date.

What does this page show?

A live price chart with SMA overlays and drawing tools for CERT, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Health Information Services, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.